肝内胆管癌的热消融治疗:安全性、疗效及影响局部肿瘤进展的因素
回顾性分析2006至2015年20例患者共50个肝内胆管癌病灶(平均大小1.8±1.3 cm)接受经皮射频或微波消融,44个(88%)用射频、6个(12%)用微波;11个(22%)病灶在5例(25%)患者出现局部肿瘤进展,中位至局部进展时间7.1个月;无重大并发症,肿瘤大小和消融方式与局部进展无关,原发肿瘤和浅表位置肿瘤更易后续复发。
要点
- 50个肝内胆管癌病灶中44个(88%)行射频消融、6个(12%)行微波消融,无重大并发症发生。
- 11个(22%)病灶发生局部肿瘤进展,中位至局部进展时间7.1个月(范围2.3-22.9个月)。
- 微波消融与射频消融相比局部肿瘤进展风险无显著差异(HR 2.72;95%CI 0.58-12.84;p=03.21)。
核心结论
- 经皮热消融对肝内胆管癌患者安全有效,可能对不可切除或已接受肝脏手术的患者尤其有价值;肿瘤大小和消融方式与局部肿瘤进展无关,而原发肿瘤和浅表位置肿瘤更易后续复发。
研究设计与样本
- 回顾性审查机构肿瘤消融登记数据库,纳入2006至2015年20例患者(9男、11女;平均年龄62.5±15.8岁)共50个肝内胆管癌病灶(平均大小1.8±1.3 cm),接受经皮射频消融或微波消融;50个病灶中38个(76%)为原发肿瘤手术切除后出现的转移灶;采用Cox比例风险模型分析消融方式与局部肿瘤进展风险,Kaplan-Meier法进行生存分析。
诊断标准与关键数值
- 微波消融对比射频消融的局部肿瘤进展风险:HR 2.72(95%CI 0.58-12.84;p=03.21),无显著差异;中位无病生存期8.2个月(范围1.1-70.4个月),中位总生存期23.6个月(范围7.4-122.5个月);平均影像随访时间41.5±42.7个月。
临床应用与阅片要点
- 作者结论认为经皮热消融对肝内胆管癌患者安全有效,可能对不可切除或已接受肝脏手术的患者尤其有价值;作者报告原发肿瘤和浅表位置肿瘤更易后续复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the safety and oncologic efficacy of percutaneous thermal ablation of intrahepatic cholangiocarcinoma (ICC) and identify risk factors for local tumor progression (LTP).
MATERIALS AND METHODS: Retrospective review of an institutional tumor ablation registry demonstrated that 20 patients (9 males, 11 females; mean age 62.5 ± 15.8 years) with 50 ICCs (mean size 1.8 ± 1.3 cm) were treated with percutaneous radiofrequency ablation (RFA) or microwave ablation (MWA) between 2006 and 2015. Thirty-eight of the treated ICCs (76%) were metastases that developed after surgical resection of the primary tumor. Patient demographics, procedure technical parameters, and clinical outcomes were reviewed. A Cox proportional hazards model was used to examine the risk of LTP by ablation modality. Survival analyses were performed using the Kaplan-Meier method.
RESULTS: Mean imaging follow-up time was 41.5 ± 42.7 months. Forty-four (88%) ICCs were treated with RFA, and 6 (12%) with MWA. Eleven (22%) cases of LTP developed in 5 (25%) patients. The median time to LTP among these 11 tumors was 7.1 months (range, 2.3-22.9 months). Risk of LTP was not significantly different for ICCs treated with MWA compared to RFA (HR 2.72; 95% CI 0.58-12.84; p = 03.21). Median disease-free survival was 8.2 months (1.1-70.4 months), and median overall survival was 23.6 months (7.4-122.5 months). No major complication occurred.
CONCLUSIONS: Percutaneous thermal ablation is a safe and effective treatment for patients with ICCs and may be particularly valuable in unresectable patients, or those who have already undergone hepatic surgery. Tumor size and ablation modality were not associated with LTP, whereas primary tumors and superficially located tumors were more likely to subsequently recur.
引用
- Takahashi EA, Kinsman KA, Schmit GD, et al. Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY). 2018. PMID: 29869103. doi:10.1007/s00261-018-1656-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。